ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Kidney transplantation"

  • 2019 American Transplant Congress

    Urine Uromodulin Associates with Deceased Donor Acute Kidney Injury and Allograft Failure

    S. G. Mansour1, I. Hall2, P. Reese3, T. Ashkar4, Y. Jia4, H. Thiessen-Philbrook4, M. Doshi5, C. R. Parikh4

    1Yale, New Haven, CT, 2University of Utah, Salt Lake City, UT, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4Johns Hopkins University, Baltimore, MD, 5University of Michigan, Ann Arbor, MI

    *Purpose: Produced exclusively by renal epithelial cells of the thick ascending limb, Uromodulin (UMOD, also known as Tamm-Horsfall protein) is the major component of hyaline…
  • 2019 American Transplant Congress

    Natural Killer Cells Express Significantly More CD16 during Chronic Active Antibody Mediated Rejection Which is Not Caused by a Single Nucleotide Polymorphism within the CD16 Gene

    K. Sablik, N. Litjens, A. Peeters, M. Clahsen-van Groningen, M. Klepper, M. Betjes

    Erasmus MC, Rotterdam, Netherlands

    *Purpose: Chronic-active antibody mediated rejection (c-aABMR) is the leading cause of long-term renal allograft loss. Fc-receptor CD16 bearing natural killer (NK) cells may be involved…
  • 2019 American Transplant Congress

    Renal Transplantation in Patients Older Than 60 Years with High Comorbidity. Is There a Survival Benefit? A Multicenter Study in Argentina

    G. D. Fragale1, G. A. Laham2, L. Bisignano3, A. Antik3, P. M. Raffaele4, M. Fortunato4, H. Trimarchi5, V. Pomeranz5, R. Maldonado6, N. Matamala6, N. C. Imperiali7, M. C. Giordani7, M. F. Taylor8, J. M. Ciappa8, J. L. De La Fuente9, S. Naser10, G. Soler Pujol2

    1Nephrology, Hospital Universitario Austral, Derqui, Argentina, 2Nephrology, CEMIC, Buenos Aires, Argentina, 3INCUCAI, Buenos Aires, Argentina, 4Fundacion Favaloro, Buenos Aires, Argentina, 5Hospital Britanico de Buenos Aires, Buenos Aires, Argentina, 6Clinica Velez Sarsfield, Cordoba, Argentina, 7Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Crai Sur, Buenos Aires, Argentina, 9Hospital Privado Universitario de Cordoba, Cordoba, Argentina, 10Hospital Privado Universitario de Cordoba, Buenos Aires, Argentina

    *Purpose: The impact of renal transplantation (RT) in the elderly with comorbid conditions is a matter of concern. Our aim was to assess the impact…
  • 2019 American Transplant Congress

    Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)

    K. Budde1, S. Bunnapradist2, S. J. Patel3, D. R. Stevens3, U. Meier-Kriesche3, B. Suwelack4

    1Charité University Medicine Berlin, Berlin, Germany, 2UCLA Medical Center, Los Angeles, CA, 3Veloxis Pharmaceuticals Inc., Cary, NC, 4University Hospital of Münster, Münster, Germany

    *Purpose: Early achievement of therapeutic tacrolimus concentrations has been associated with reduced rates of acute rejection. A prospective, randomized, controlled study demonstrated safe and efficacious…
  • 2019 American Transplant Congress

    Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation 5 Years Results

    Y. Watarai1, S. Narumi1, T. Tomosugi1, M. Okada1, K. Futamura2, M. Tsujita2, T. Hiramitsu1, T. Kobayashi3, N. Goto2

    1Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 2Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 3Kidney Transplant Surgery, Aichi Medical University, Nagoya, Japan

    *Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…
  • 2019 American Transplant Congress

    Phenotype and Course of Renal Tubular Cell Death during Cold Ischemia versus Cold Ischemia Followed by Transplant

    S. Jain1, R. Plenter2, T. Nydam2, A. Jani1

    1Renal Division, University of Colorado, Aurora, CO, 2Transplant Microsurgery Program, University of Colorado, Aurora, CO

    *Purpose: Treatments of Delayed graft function (DGF) are lacking. Prolonged cold ischemia (CI) is a risk factor for DGF but the pathways by which CI…
  • 2019 American Transplant Congress

    Post-Transplant Lymphopenia is Associated with Higher Risk of Graft Failure, Death and Viral Infections

    A. Dujardin1, M. Lorent2, C. Kerleau1, S. Brouard3, M. Giral1

    1Nephrology, Nantes University Hospital, Nantes, France, 2UMR_S 1246, INSERM, Nantes, France, 3CRTI  UMR 1064, Inserm, Nantes, France

    *Purpose: The transplantation field needs biomarkers to assess the level of immunosuppression. In this study, we aimed to analyze the independent correlation between the number…
  • 2019 American Transplant Congress

    Individualized Preconditioning for ABO-Incompatible Living Donor Kidney Transplantation: An Initial Report of 48 Cases from China

    X. -. Wang

    Department of Urology/Institute of Urology, West China Hospital of Sichuan University, Chengdu, China

    *Purpose: Typically, the majority of centres that perform ABO incompatible (ABOi) kidney transplantation use fixed preconditioning protocols regardless of the initial titer. As experience in…
  • 2019 American Transplant Congress

    Kidney Transplants Following Donation after Circulatory Death and Donation after Brain Death Have Similar Early Outcomes

    M. Hobeika1, D. Nguyen2, E. Graviss2, A. Gaber1, H. Podder1, S. Yi1, S. Kuten3, S. Patel3, R. Knight1

    1J.C. Walter, Jr. Transplant Center, Houston Methodist Hospital, Houston, TX, 2Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, TX, 3Pharmacy, Houston Methodist Hospital, Houston, TX

    *Purpose: Donation after circulatory death (DCD) is common in the US, comprising 18.3% of the deceased donor pool in 2017. Recipient outcomes following DCD kidney…
  • 2019 American Transplant Congress

    Thymoglobulin Versus Alemtuzumab Induction in High Immunologic Risk Kidney Transplants

    J. Lockridge1, J. Pryor1, D. Norman1, A. Olyaei2

    1OHSU, Portland, OR, 2Pharmacy, OHSU, Portland, OR

    *Purpose: The optimal induction immunosuppressive therapy to prevent kidney transplant rejection remains controversial, specifically among high immunologic risk patients. Our aim was to compare the…
  • « Previous Page
  • 1
  • …
  • 202
  • 203
  • 204
  • 205
  • 206
  • …
  • 531
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences